Ga-ABY-025
Phase 1Small molecule
Ga-ABY-025 is one of 16 small molecule programs targeting Targeted Therapy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
18 competitors in Targeted Therapy
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 3
Xospata
AstellasPhase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Gazyva
RochePhase 2
Tafinlar
NovartisPhase 2
Fasenra
AstraZenecaPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Braftovi
PfizerPhase 2
Tuoyi
CCoherus Oncology, Inc.
Phase 2
Nublexa
BBeijing InnoCare Pharma Tech Co., Ltd.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ga-ABY-025. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- VVanderbilt-Ingram Cancer Center